MA52360A - Dérivés de 2-amino-pyridine ou de 2-amino-pyrimidine utilisés en tant qu'inhibiteurs de kinases dépendantes des cyclines - Google Patents
Dérivés de 2-amino-pyridine ou de 2-amino-pyrimidine utilisés en tant qu'inhibiteurs de kinases dépendantes des cyclinesInfo
- Publication number
- MA52360A MA52360A MA052360A MA52360A MA52360A MA 52360 A MA52360 A MA 52360A MA 052360 A MA052360 A MA 052360A MA 52360 A MA52360 A MA 52360A MA 52360 A MA52360 A MA 52360A
- Authority
- MA
- Morocco
- Prior art keywords
- amino
- cycline
- pyridine
- kinase inhibitors
- dependent kinase
- Prior art date
Links
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 title 2
- 150000005006 2-aminopyrimidines Chemical class 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862663096P | 2018-04-26 | 2018-04-26 | |
| US201862750454P | 2018-10-25 | 2018-10-25 | |
| US201962826609P | 2019-03-29 | 2019-03-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52360A true MA52360A (fr) | 2021-03-03 |
Family
ID=66676856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052360A MA52360A (fr) | 2018-04-26 | 2019-04-22 | Dérivés de 2-amino-pyridine ou de 2-amino-pyrimidine utilisés en tant qu'inhibiteurs de kinases dépendantes des cyclines |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US10766884B2 (fr) |
| EP (1) | EP3784664A1 (fr) |
| JP (2) | JP7089061B2 (fr) |
| KR (2) | KR102596598B1 (fr) |
| CN (1) | CN112313219B (fr) |
| AU (1) | AU2019259653B2 (fr) |
| BR (1) | BR112020021689B1 (fr) |
| CA (1) | CA3098283C (fr) |
| CL (1) | CL2020002748A1 (fr) |
| CO (1) | CO2020013149A2 (fr) |
| CR (1) | CR20200503A (fr) |
| CU (1) | CU20200070A7 (fr) |
| DO (1) | DOP2020000191A (fr) |
| EC (1) | ECSP20067394A (fr) |
| GE (1) | GEP20227433B (fr) |
| IL (1) | IL278075B2 (fr) |
| MA (1) | MA52360A (fr) |
| MX (1) | MX2020011294A (fr) |
| NI (1) | NI202000072A (fr) |
| PE (1) | PE20201202A1 (fr) |
| PH (1) | PH12020551692A1 (fr) |
| RU (1) | RU2762557C1 (fr) |
| SG (1) | SG11202009992VA (fr) |
| TW (1) | TWI740135B (fr) |
| UA (1) | UA126177C2 (fr) |
| UY (1) | UY38196A (fr) |
| WO (1) | WO2019207463A1 (fr) |
| ZA (1) | ZA202006944B (fr) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201811799A (zh) | 2016-09-09 | 2018-04-01 | 美商英塞特公司 | 吡唑并嘧啶化合物及其用途 |
| WO2018049214A1 (fr) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Dérivés de pyrazolopyridine comme modulateurs de hpk1 et leurs utilisations pour le traitement du cancer |
| IL292977A (en) | 2016-09-09 | 2022-07-01 | Incyte Corp | Pyrazolopyridine derivatives as modulators of hpk1 and their use in cancer therapy |
| US10752635B2 (en) | 2018-02-20 | 2020-08-25 | Incyte Corporation | Indazole compounds and uses thereof |
| MD3755703T2 (ro) | 2018-02-20 | 2022-10-31 | Incyte Corp | Derivați N-(fenil)-2-(fenil)pirimidin-4-carboxamidă și compuși înrudiți ca inhibitori HPK1 pentru tratarea cancerului |
| MA52360A (fr) | 2018-04-26 | 2021-03-03 | Pfizer | Dérivés de 2-amino-pyridine ou de 2-amino-pyrimidine utilisés en tant qu'inhibiteurs de kinases dépendantes des cyclines |
| US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
| US11472791B2 (en) | 2019-03-05 | 2022-10-18 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors |
| US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
| WO2020223469A1 (fr) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Dérivés de n-(1-(méthylsulfonyl)pipéridin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine et composés apparentés utilisés en tant qu'inhibiteurs de kinase 2 dépendante des cyclines (cdk2) pour le traitement du cancer |
| US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| CA3147918A1 (fr) | 2019-08-06 | 2021-02-11 | Incyte Corporation | Formes solides d'un inhibiteur d'hpk 1 |
| JP2023509260A (ja) | 2019-08-14 | 2023-03-08 | インサイト・コーポレイション | Ｃｄｋ２阻害剤としてのイミダゾリルピリミジニルアミン化合物 |
| US11038699B2 (en) * | 2019-08-29 | 2021-06-15 | Advanced New Technologies Co., Ltd. | Method and apparatus for performing multi-party secure computing based-on issuing certificate |
| AR120184A1 (es) | 2019-10-11 | 2022-02-02 | Incyte Corp | Aminas bicíclicas como inhibidoras de la cdk2 |
| CN116113407A (zh) | 2020-07-15 | 2023-05-12 | 辉瑞公司 | 用于癌症治疗的kat6抑制剂方法及组合 |
| JP2023537595A (ja) | 2020-08-13 | 2023-09-04 | ファイザー・インク | 併用治療 |
| CN112028834B (zh) * | 2020-09-11 | 2022-03-29 | 济南悟通生物科技有限公司 | 一种阿贝西利的中间体的合成方法 |
| CA3195063A1 (fr) * | 2020-09-15 | 2022-03-24 | Pfizer Inc. | Formes solides d'un inhibiteur de cdk4 |
| CN112679522B (zh) * | 2020-12-29 | 2023-02-14 | 南京正济医药研究有限公司 | 一种巴洛沙韦中间体的制备方法 |
| WO2022149057A1 (fr) * | 2021-01-05 | 2022-07-14 | Rhizen Pharmaceuticals Ag | Inhibiteurs de cdk |
| TW202231282A (zh) | 2021-02-03 | 2022-08-16 | 大陸商上海拓界生物醫藥科技有限公司 | 稠三環類細胞週期蛋白－依賴性激酶抑制劑及其製備方法和醫藥用途 |
| WO2023100134A1 (fr) | 2021-12-02 | 2023-06-08 | Pfizer Inc. | Méthodes et schémas posologiques comprenant un inhibiteur de cdk2 et un inhibiteur de cdk4 pour le traitement du cancer |
| WO2023100070A1 (fr) | 2021-12-02 | 2023-06-08 | Pfizer Inc. | Inhibiteur de cdk4 pour le traitement du cancer |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| WO2023116862A1 (fr) * | 2021-12-24 | 2023-06-29 | 江苏恒瑞医药股份有限公司 | Composé indole hydrogéné, son procédé de préparation et son utilisation médicale |
| WO2024022487A1 (fr) * | 2022-07-29 | 2024-02-01 | Allorion Therapeutics Inc | Inhibiteurs d'aminohétéroaryl kinase |
| WO2024023703A1 (fr) | 2022-07-29 | 2024-02-01 | Pfizer Inc. | Schémas posologiques comprenant un inhibiteur de kat6 pour le traitement du cancer |
| TW202406912A (zh) * | 2022-08-01 | 2024-02-16 | 大陸商江蘇恒瑞醫藥股份有限公司 | 稠三環類衍生物的晶型及製備方法 |
| WO2024051702A1 (fr) * | 2022-09-05 | 2024-03-14 | 浙江同源康医药股份有限公司 | Composé utilisé comme inhibiteur de la kinase cdk4 et son utilisation |
| WO2024066986A1 (fr) * | 2022-09-30 | 2024-04-04 | 楚浦创制（武汉）医药科技有限公司 | Composé de 2-aminopyrimidine, utilisation et composition pharmaceutique de celui-ci |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (fr) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing-gum contenant des agents medicamenteux actifs |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| MX228790B (es) | 1999-09-17 | 2005-06-30 | Millennium Pharm Inc | Inhibidores del factor xa. |
| AU2001250783A1 (en) | 2000-02-29 | 2001-09-12 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| US20040171630A1 (en) | 2001-06-19 | 2004-09-02 | Yuntae Kim | Tyrosine kinase inhibitors |
| GB0308466D0 (en) | 2003-04-11 | 2003-05-21 | Novartis Ag | Organic compounds |
| GB0317127D0 (en) * | 2003-07-22 | 2003-08-27 | Astex Technology Ltd | Pharmaceutical compounds |
| KR101204247B1 (ko) | 2003-07-22 | 2012-11-22 | 아스텍스 테라퓨틱스 리미티드 | 3,4-이치환된 1ｈ-피라졸 화합물 및 그의 시클린 의존성키나제 (ｃｄｋ) 및 글리코겐 합성효소 키나제-3(ｇｓｋ-3) 조정제로서 용도 |
| WO2006038001A1 (fr) | 2004-10-06 | 2006-04-13 | Celltech R & D Limited | Derives d’aminopyrimidine en tant qu’inhibiteurs de la jnk |
| EP2086970B1 (fr) * | 2006-08-24 | 2014-02-26 | Novartis AG | Dérivés de 2-(pyrazin-2-yl)-thiazole et de 2-(1h pyrazol-3-yl)-thiazole et composés similaires en tant qu' inhibiteurs de stearoyl-coa desaturase (scd) pour le traitement de maladies metaboliques, cardiovasculaires et d'autres maladies |
| KR20110025224A (ko) | 2008-06-27 | 2011-03-09 | 아빌라 테라퓨틱스, 인크. | 헤테로아릴 화합물 및 이의 용도 |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| WO2010069833A1 (fr) | 2008-12-19 | 2010-06-24 | F. Hoffmann-La Roche Ag | Dérivés pyrimidin-2-ylamino et leur utilisation dans le traitement d'une inflammation |
| JO2885B1 (en) | 2008-12-22 | 2015-03-15 | ايلي ليلي اند كومباني | Protein kinase inhibitors |
| KR101481872B1 (ko) | 2009-09-10 | 2015-01-12 | 에프. 호프만-라 로슈 아게 | Ｊａｋ의 억제제 |
| EP2569302A1 (fr) | 2010-05-13 | 2013-03-20 | Amgen, Inc | Composés d'hétéroaryloxyhétérocyclyle convenant comme inhibiteurs de la pde10 |
| WO2012129562A2 (fr) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Composés et procédés pour l'induction de la chondrogenèse |
| JO3300B1 (ar) | 2012-06-06 | 2018-09-16 | Novartis Ag | مركبات وتركيبات لتعديل نشاط egfr |
| TW201444820A (zh) * | 2013-03-13 | 2014-12-01 | Abbvie Inc | 吡啶ｃｄｋ９激酶抑制劑 |
| AU2013399092A1 (en) | 2013-08-30 | 2016-03-17 | Ptc Therapeutics, Inc. | Substituted pyrimidine Bmi-1 inhibitors |
| US20160264552A1 (en) | 2013-10-18 | 2016-09-15 | Syros Pharmaceuticals, Inc. | Heteromaromatic compounds useful for the treatment of prolferative diseases |
| WO2015103133A1 (fr) | 2013-12-30 | 2015-07-09 | Genentech, Inc. | Inhibiteurs de sérine/thréonine kinases |
| ES2702951T3 (es) | 2014-04-04 | 2019-03-06 | Syros Pharmaceuticals Inc | Inhibidores de quinasas dependientes de ciclina 7 (cdk7) |
| MY187555A (en) | 2014-07-24 | 2021-09-29 | Beta Pharma Inc | 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof |
| CN105294655B (zh) | 2014-07-26 | 2019-03-15 | 广东东阳光药业有限公司 | Cdk类小分子抑制剂的化合物及其用途 |
| CN115925679A (zh) | 2014-12-24 | 2023-04-07 | 株式会社Lg化学 | 作为gpr120激动剂的联芳基衍生物 |
| WO2016192630A1 (fr) | 2015-06-01 | 2016-12-08 | 中国科学院上海药物研究所 | Composé présentant une activité inhibitrice de kinase, son procédé de préparation, et utilisation de celui-ci |
| EP3313530B1 (fr) | 2015-06-26 | 2022-10-05 | Dana Farber Cancer Institute, Inc. | Dérivés de 4,6-pyrimidinylène et utilisations de ceux-ci |
| CN105111191B (zh) * | 2015-07-21 | 2018-06-08 | 上海皓元生物医药科技有限公司 | 一种用于合成cdk9抑制剂的关键中间体及其制备方法和用途 |
| CN106928216A (zh) | 2015-12-31 | 2017-07-07 | 中国科学院上海药物研究所 | 具有erk激酶抑制活性的化合物、其制备方法和用途 |
| CN108602799B (zh) | 2016-02-06 | 2021-08-03 | 上海复尚慧创医药研究有限公司 | 一类激酶抑制剂 |
| EP4295852A2 (fr) * | 2016-07-13 | 2023-12-27 | Syros Pharmaceuticals, Inc. | Inhibiteurs de la kinase 7 dépendante des cyclines (cdk7) |
| WO2018161033A1 (fr) | 2017-03-02 | 2018-09-07 | Wright, Adrian | Inhibiteurs ire1-alpha à petites molécules |
| CN109843872B (zh) | 2017-09-20 | 2022-08-30 | 杭州英创医药科技有限公司 | 作为ido抑制剂和/或ido-hdac双重抑制剂的多环化合物 |
| MA52360A (fr) | 2018-04-26 | 2021-03-03 | Pfizer | Dérivés de 2-amino-pyridine ou de 2-amino-pyrimidine utilisés en tant qu'inhibiteurs de kinases dépendantes des cyclines |
-
2019
- 2019-04-22 MA MA052360A patent/MA52360A/fr unknown
- 2019-04-22 CN CN201980042382.5A patent/CN112313219B/zh active Active
- 2019-04-22 RU RU2020134811A patent/RU2762557C1/ru active
- 2019-04-22 PE PE2020001635A patent/PE20201202A1/es unknown
- 2019-04-22 BR BR112020021689-5A patent/BR112020021689B1/pt active IP Right Grant
- 2019-04-22 CR CR20200503A patent/CR20200503A/es unknown
- 2019-04-22 AU AU2019259653A patent/AU2019259653B2/en active Active
- 2019-04-22 EP EP19727502.7A patent/EP3784664A1/fr active Pending
- 2019-04-22 CA CA3098283A patent/CA3098283C/fr active Active
- 2019-04-22 GE GEAP201915475A patent/GEP20227433B/en unknown
- 2019-04-22 MX MX2020011294A patent/MX2020011294A/es unknown
- 2019-04-22 KR KR1020207033931A patent/KR102596598B1/ko active Application Filing
- 2019-04-22 CU CU2020000070A patent/CU20200070A7/es unknown
- 2019-04-22 UA UAA202006733A patent/UA126177C2/uk unknown
- 2019-04-22 SG SG11202009992VA patent/SG11202009992VA/en unknown
- 2019-04-22 WO PCT/IB2019/053314 patent/WO2019207463A1/fr active Application Filing
- 2019-04-22 KR KR1020237036862A patent/KR102661053B1/ko active IP Right Grant
- 2019-04-22 JP JP2020560277A patent/JP7089061B2/ja active Active
- 2019-04-23 TW TW108114112A patent/TWI740135B/zh active
- 2019-04-23 US US16/391,836 patent/US10766884B2/en active Active
- 2019-04-24 UY UY0001038196A patent/UY38196A/es unknown
-
2020
- 2020-07-29 US US16/942,209 patent/US11220494B2/en active Active
- 2020-10-13 PH PH12020551692A patent/PH12020551692A1/en unknown
- 2020-10-15 IL IL278075A patent/IL278075B2/en unknown
- 2020-10-21 EC ECSENADI202067394A patent/ECSP20067394A/es unknown
- 2020-10-21 CO CONC2020/0013149A patent/CO2020013149A2/es unknown
- 2020-10-22 NI NI202000072A patent/NI202000072A/es unknown
- 2020-10-23 DO DO2020000191A patent/DOP2020000191A/es unknown
- 2020-10-23 CL CL2020002748A patent/CL2020002748A1/es unknown
- 2020-11-06 ZA ZA2020/06944A patent/ZA202006944B/en unknown
-
2021
- 2021-12-07 US US17/544,303 patent/US20220089580A1/en active Pending
-
2022
- 2022-06-09 JP JP2022093962A patent/JP2022120096A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52360A (fr) | Dérivés de 2-amino-pyridine ou de 2-amino-pyrimidine utilisés en tant qu'inhibiteurs de kinases dépendantes des cyclines | |
| MA51846A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinases | |
| MA49888A (fr) | Composés macrocycliques utilisés en tant qu'inhibiteurs de kinase ros1 | |
| MA53675A (fr) | Composés substitués de pyrazolo[1,5-a]pyridine en tant qu'inhibiteurs de la kinase ret | |
| MA47086A (fr) | Dérivés de dihydropyrimidine-carboxamide bicycliques utilisés en tant qu'inhibiteurs de rho-kinase | |
| MA53487A (fr) | Composés pyrazolo[3,4-b]pyridine utilisés en tant qu'inhibiteurs de kinases tam et met | |
| MA54076A (fr) | 2-amino-n-hétéroaryl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8 | |
| MA51429A (fr) | Dérivés amino-fluoropipéridines utilisés en tant qu'inhibiteur de kinase | |
| PH12018502102A1 (en) | Pyrrolotriazine compounds as tam inhibitors | |
| MA47120A (fr) | Dérivés pyridine utilisés en tant qu'immunomodulateurs | |
| MA47591A (fr) | Dérivés de [1,2,4]-triazolo [1,5-a]-pyrimidinyle substitués par de la pipéridine, de la morpholine ou de la pipérazine utilisés en tant qu'inhibiteurs d'oga | |
| MA43169A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma | |
| EA201890001A1 (ru) | Замещенные гетероциклические производные как ингибиторы циклинзависимой киназы (cdk) | |
| MA49956A (fr) | Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak | |
| MA52940A (fr) | Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b | |
| MA51431A (fr) | Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase | |
| MA42659A (fr) | Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp | |
| PH12018501413A1 (en) | Substituted thiohydantoin derivatives as androgen receptor antagonists | |
| MA47460A (fr) | Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase | |
| MA45918A (fr) | Dérivés hétérocycliques bicycliques condensés utilisés comme pesticides | |
| EA202091475A1 (ru) | ПРОИЗВОДНЫЕ 5-(2-(2,5-ДИФТОРФЕНИЛ)ПИРРОЛИДИН-1-ИЛ)-3-(1H-ПИРАЗОЛ-1-ИЛ)ПИРАЗОЛО[1,5-а]ПИРИМИДИНА И РОДСТВЕННЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Trk КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ РАКА | |
| MA51133A (fr) | Dérivés de pyrrole utilisés en tant qu'inhibiteurs d'acc | |
| MA50356A (fr) | Composés bicycliques destinés à être utilisés en tant qu'inhibiteurs de la kinase rip1 | |
| MA49374A (fr) | Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine | |
| EA201690523A1 (ru) | Триазолопиридины, композиции и способы их применения |